Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
The Korean Journal of Internal Medicine
;
: 178-185, 2007.
Artículo
en Inglés
| WPRIM
| ID: wpr-7461
ABSTRACT
BACKGROUND:
Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting.METHODS:
Docetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed.RESULTS:
From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval 8.3~13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval 1.9~4.0) and 2.8 months (95% confidence interval 1.0~4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week 38.9%, weekly 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths.CONCLUSIONS:
A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Esquema de Medicación
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Carcinoma de Pulmón de Células no Pequeñas
/
Taxoides
/
Neoplasias Pulmonares
/
Estadificación de Neoplasias
/
Antineoplásicos
Tipo de estudio:
Estudio observacional
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
The Korean Journal of Internal Medicine
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS